Tyra Biosciences

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Companys in-house precision medicine platform, SNAP, enables the rapid and precise refinement of structural drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRAs initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in Carlsbad, CA

Biotechnology,oncology,achondroplasia,fgfr biology,and structural drug design

Tyra biosciences operates in the Biotechnology industry.

Tyra biosciences's revenue is 11m - 100m

Tyra biosciences has 51 - 200 employees.